<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1129</ReferenceId>
        <DateLastUpdated>2011-08-23-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15956596</PubmedId>
            <Abstract>Antigenic variation is a viral strategy exploited to promote survival in the face of the host immune response and represents a major challenge for efficient vaccine development. Influenza viruses are pathogens with high transmissibility and mutation rates, enabling viral escape from immunity induced by prior infection or vaccination. Intense selection from neutralizing antibody drives antigenic changes in the surface glycoproteins, resulting in emergence of new strains able to reinfect hosts immune to previously circulating viruses. CD8+ cytotoxic T cells (CTLs) also provide protective immunity from influenza virus infection and may contribute to the antigenic evolution of influenza viruses. Utilizing mice transgenic for an influenza virus NP366-374 peptide-specific T-cell receptor, we demonstrated that the respiratory tract is a suitable site for generation of escape variants of influenza virus selected by CTL in vivo. In this report the contributions of the perforin and Fas pathways utilized by influenza virus-specific CTLs in viral clearance and selection of CTL escape variants have been evaluated. While transgenic CTLs deficient in either perforin- or Fas-mediated pathways are efficient in initial pulmonary viral control, variant virus emergence was observed in all the mice studied, although the spectrum of viral CTL escape variants selected varied profoundly. Thus, a less-restricted repertoire of escape variants was observed in mice with an intact perforin cytotoxic pathway compared with a limited variant diversity in perforin pathway-deficient mice, although maximal variant diversity was observed in mice having both Fas and perforin pathways intact. We conclude that selection of viral CTL escape variants reflects coordinate action between the tightly controlled perforin/granzyme pathway and the more promiscuous Fas/FasL pathway.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>8545-59</ArticlePages>
            <ArticleTitle>Perforin and Fas cytolytic pathways coordinately shape the selection and diversity of CD8+-T-cell escape variants of influenza virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Price</LastName>
                    <ForeName>Graeme E</ForeName>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Lei</ForeName>
                </Author>
                <Author>
                    <LastName>Ou</LastName>
                    <ForeName>Rong</ForeName>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Menghua</ForeName>
                </Author>
                <Author>
                    <LastName>Moskophidis</LastName>
                    <ForeName>Demetrius</ForeName>
                </Author>
            </Authors>
            <Affiliations>Institute of Molecular Medicine and Genetics, Medical College of Georgia, 1120 15th Street, CB-2803, Augusta, Georgia 30912-3175, USA.</Affiliations>
            <ArticleChemicalList>Antigens, CD95;DNA Primers;Fas Ligand Protein;Fasl protein, mouse;Homeodomain Proteins;Membrane Glycoproteins;Pore Forming Cytotoxic Proteins;Perforin;RAG-1 protein</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antigens, CD95(physiology); Base Sequence; CD8-Positive T-Lymphocytes(immunology); DNA Primers; Fas Ligand Protein; Genetic Variation; Homeodomain Proteins(genetics; physiology); Membrane Glycoproteins(deficiency; genetics; physiology); Mice; Mice, Knockout; Mice, Transgenic; Orthomyxoviridae(genetics); Perforin; Pore Forming Cytotoxic Proteins</ArticleMeshHeadingsList>
            <Journal>
                <Volume>79</Volume>
                <Issue>13</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP366-374</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASNENMDTM</LinearSequence>
                        <StartingPosition>366</StartingPosition>
                        <EndingPosition>374</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q08041</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>385640</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>P. 8546</LocationOfData>
                <EpitopeId>4580</EpitopeId>
                <ReferenceStartingPosition>366</ReferenceStartingPosition>
                <ReferenceEndingPosition>374</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The role of the perforin (P) and Fas pathways utilized by influenza virus-specific CTLs in selection of CTL escape variants was evaluated. As expected, isolates derived from F5–RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt;-P&lt;SUP&gt;-/-&lt;/SUP&gt; or F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt;–FasL&lt;SUP&gt;-/-&lt;/SUP&gt; mice at later time points in the infection revealed the appearance of amino acid substitutions within the NP366-374 epitope at TCR contact residues (positions 371 and 372) or MHC anchor residues (positions 370 and 374). However, isolates derived from F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt;-P&lt;SUP&gt;-/-&lt;/SUP&gt; mice showed a more limited spectrum of variation than those derived from F5–RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt; or F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt;-FasL&lt;SUP&gt;-/-&lt;/SUP&gt; mice. While in all three mouse strains the most commonly observed variation was the 371 M3I mutant, which effectively abrogates recognition of the NP366-374 peptide by the transgenic F5-TCR, a wide diversity of mutations predicted to affect either TCR recognition or peptide binding to MHC were clearly observed in perforin-sufficient mice. However, the maximal diversity of variant virus was observed where both perforin and Fas/FasL pathways were intact, suggesting interplay between these two mechanisms.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 7</LocationOfData>
                        <TCellId>15838</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000074</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were uninfected.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000067</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP366-374</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASNENMDTM</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>374</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q08041</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Splenocytes from uninfected mice transgenic for an influenza virus NP366-374 peptide-specific T-cell receptor were assayed for proliferation in response to peptide stimulation. Similar results were seen when the infected host was C57BL/6 F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt;  Perforin&lt;SUP&gt;-/-&lt;/SUP&gt;, C57BL/6  F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt; FastL&lt;SUP&gt;-/-&lt;/SUP&gt;, or C57BL/6  F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt; Perforin&lt;SUP&gt;-/-&lt;/SUP&gt; FastL&lt;SUP&gt;-/-&lt;/SUP&gt;, indicating that there are no inherent defects in the ability of CTL from these mice to recognize and respond to their cognate MHC-peptide ligand.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15716</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1x</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP366-374</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASNENMDTM</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>374</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q08041</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system. Intracellular IFN-γ was also detected with IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-FasL&lt;SUP&gt;-/-&lt;/SUP&gt; or IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-Perforin&lt;SUP&gt;-/-&lt;/SUP&gt; mice, however, a large portion of the IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-Perforin&lt;SUP&gt;-/-&lt;/SUP&gt; mice were unable to efficiently clear virus between days 7 and 10. This suggests that antiviral protection is more efficiently mediated via perforin than by FasL-dependent pathways ina host without antiviral antibodies. Intracellular IFN-γ was also detected in with lymphocytes from the lungs of mice (F5-Rag-1&lt;SUP&gt;-/-&lt;/SUP&gt;) transgenic for an influenza virus NP366-374 peptide-specific T-cell receptor. Note that the transgenic C57BL/6 F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt; mouse contains a high frequency of antiinfluenza CTL precursors, but no protective antibodies. Similar results were seen when the infected host was F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt;  Perforin&lt;SUP&gt;-/-&lt;/SUP&gt;, F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt; FastL&lt;SUP&gt;-/-&lt;/SUP&gt;, or F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt; Perforin&lt;SUP&gt;-/-&lt;/SUP&gt; FastL&lt;SUP&gt;-/-&lt;/SUP&gt;, suggesting that the activation of transgenic CTL in the lung was not affected by the deficiency in either perforin, FasL, or both. When cells from the spleen were studied, only a fraction of the splenocytes were able to produce IFN-γ in response to peptide stimulation as compared to lung CTL which were uniformly able to able to produce IFN-γ on peptide stimulation.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15718</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Day 0 (primary), Day 32 (secondary)</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>At day 0, the mice were primed with Influenza virus A/Memphis/102/72 (H3N2). At day 32, the mice were challenged with reassortant influenza virus (A/MemH1N1) bearing the HA and NA of A/PR/8/34 but with all other genes derived from A/Mem.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP366-374</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASNENMDTM</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>374</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q08041</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system. At 10 days post challenge, the epitope-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T cells comprised 65.4 % of the virus-specific T cells in a C57BL/6 host, 50.2% of the virus-specific T cells in a C57BL/6 perforin-deficient host  and 40.0% of the virus-specific T cells in a C57BL/6 FasL-deficient host.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15719</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Day 0 (primary), Day 32 (secondary)</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>At day 0, the mice were primed with Influenza virus A/Memphis/102/72 (H3N2). At day 32, the mice were challenged with reassortant influenza virus (A/MemH1N1) bearing the HA and NA of A/PR/8/34 but with all other genes derived from A/Mem.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP366-374</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASNENMDTM</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>374</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q08041</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15713</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1x</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP366-374</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASNENMDTM</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>374</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q08041</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system. At 10 days post infection, the epitope-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T cells comprised 38.1 % of the virus-specific T cells in a C57BL/6 host, 20.9% of the virus-specific T cells in a C57BL/6 perforin-deficient host  and 17.7% of the virus-specific T cells in a C57BL/6 FasL-deficient host. Virus-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T cells were also detected in tetramer-binding experiments  with IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-FasL&lt;SUP&gt;-/-&lt;/SUP&gt; or IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-Perforin&lt;SUP&gt;-/-&lt;/SUP&gt; mice, however, a large portion of the IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-Perforin&lt;SUP&gt;-/-&lt;/SUP&gt; mice were unable to efficiently clear virus between days 7 and 10. This suggests that antiviral protection is more efficiently mediated via perforin than by FasL-dependent pathways in a host without antiviral antibodies. Virus-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T cells were also detected in tetramer-binding experiments  with lymphocytes from the lungs of mice (F5-Rag-1&lt;SUP&gt;-/-&lt;/SUP&gt;) transgenic for an influenza virus NP366-374 peptide-specific T-cell receptor. Note that the transgenic C57BL/6 F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt; mouse contains a high frequency of antiinfluenza CTL precursors, but no protective antibodies. Similar results were seen when the infected mouse was F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt;  Perforin&lt;SUP&gt;-/-&lt;/SUP&gt;, F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt; FastL&lt;SUP&gt;-/-&lt;/SUP&gt;, or F5-RAG-1&lt;SUP&gt;-/-&lt;/SUP&gt; Perforin&lt;SUP&gt;-/-&lt;/SUP&gt; FastL&lt;SUP&gt;-/-&lt;/SUP&gt;, suggesting that the recruitment of transgenic CTL to the lung was not affected by the deficiency in either perforin, FasL, or both. Similar results were found for splenocytes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>PA224-233</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SCLENFRAYV</LinearSequence>
                        <StartingPosition>224</StartingPosition>
                        <EndingPosition>233</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>71842561</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>385640</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>P. 8546</LocationOfData>
                <EpitopeId>57105</EpitopeId>
                <ReferenceStartingPosition>224</ReferenceStartingPosition>
                <ReferenceEndingPosition>233</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15854</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1x</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA224-233</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SCLENFRAYV</LinearSequence>
                                        <StartingPosition>224</StartingPosition>
                                        <EndingPosition>233</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>71842561</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system. At 10 days post infection, the epitope-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T cells comprised 7.1 % of the virus-specific T cells in a C57BL/6 host, 16.9% of the virus-specific T cells in a C57BL/6 perforin-deficient host  and 16.9% of the virus-specific T cells in a C57BL/6 FasL-deficient host. Virus-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T cells were also detected in tetramer-binding experiments  with IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-FasL&lt;SUP&gt;-/-&lt;/SUP&gt; or IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-Perforin&lt;SUP&gt;-/-&lt;/SUP&gt; mice, however, a large portion of the IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-P&lt;SUP&gt;-/-&lt;/SUP&gt; mice were unable to able to efficiently clear virus between days 7 and 10. This suggests that antiviral protection is more efficiently mediated via perforin than by FasL-dependent pathways in a host without antiviral antibodies.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15855</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1x</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA224-233</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SCLENFRAYV</LinearSequence>
                                        <StartingPosition>224</StartingPosition>
                                        <EndingPosition>233</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>71842561</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system. Intracellular IFNγ was also detected with IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-FasL&lt;SUP&gt;-/-&lt;/SUP&gt; or IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-Perforin&lt;SUP&gt;-/-&lt;/SUP&gt; mice, however, a large portion of the IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-P&lt;SUP&gt;-/-&lt;/SUP&gt; mice were unable to able to efficiently clear virus between days 7 and 10. This suggests that antiviral protection is more efficiently mediated via perforin than by FasL-dependent pathways in a host without antiviral antibodies.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15856</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Day 0 (primary), Day 32 (secondary)</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>At day 0, the mice were primed with Influenza virus A/Memphis/102/72 (H3N2). At day 32, the mice were challenged with reassortant influenza virus (A/MemH1N1) bearing the HA and NA of A/PR/8/34 but with all other genes derived from A/Mem.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA224-233</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SCLENFRAYV</LinearSequence>
                                        <StartingPosition>224</StartingPosition>
                                        <EndingPosition>233</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>71842561</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system. At 10 days post challenge, the epitope-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T cells comprised 4.7 % of the virus-specific T cells in a C57BL/6 host, 15.9% of the virus-specific T cells in a C57BL/6 perforin-deficient host  and 5.5% of the virus-specific T cells in a C57BL/6 FasL-deficient host.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15857</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Day 0 (primary), Day 32 (secondary)</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>At day 0, the mice were primed with Influenza virus A/Memphis/102/72 (H3N2). At day 32, the mice were challenged with reassortant influenza virus (A/MemH1N1) bearing the HA and NA of A/PR/8/34 but with all other genes derived from A/Mem.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA224-233</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SCLENFRAYV</LinearSequence>
                                        <StartingPosition>224</StartingPosition>
                                        <EndingPosition>233</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>71842561</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NS2_114-121</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RTFSFQLI</LinearSequence>
                        <StartingPosition>114</StartingPosition>
                        <EndingPosition>121</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>138967</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>385640</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>P. 8546</LocationOfData>
                <EpitopeId>56055</EpitopeId>
                <ReferenceStartingPosition>114</ReferenceStartingPosition>
                <ReferenceEndingPosition>121</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15891</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1x</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NS2_114-121</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RTFSFQLI</LinearSequence>
                                        <StartingPosition>114</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>138967</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system. At 10 days post infection, the epitope-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T cells comprised 9.5 % of the virus-specific T cells in a C57BL/6 host, 11.3% of the virus-specific T cells in a C57BL/6 perforin-deficient host  and 5.5% of the virus-specific T cells in a C57BL/6 FasL-deficient host. Virus-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T cells were also detected in tetramer-binding experiments  with IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-FasL&lt;SUP&gt;-/-&lt;/SUP&gt; or IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-Perforin&lt;SUP&gt;-/-&lt;/SUP&gt; mice. However, a large portion of the IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-P&lt;SUP&gt;-/-&lt;/SUP&gt; mice were unable to able to efficiently clear virus between days 7 and 10. This suggests that antiviral protection is more efficiently mediated via perforin than by FasL-dependent pathways in a host without antiviral antibodies.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15894</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Day 0 (primary), Day 32 (secondary)</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>At day 0, the mice were primed with Influenza virus A/Memphis/102/72 (H3N2). At day 32, the mice were challenged with reassortant influenza virus (A/MemH1N1) bearing the HA and NA of A/PR/8/34 but with all other genes derived from A/Mem.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NS2_114-121</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RTFSFQLI</LinearSequence>
                                        <StartingPosition>114</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>138967</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15893</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Day 0 (primary), Day 32 (secondary)</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>At day 0, the mice were primed with Influenza virus A/Memphis/102/72 (H3N2). At day 32, the mice were challenged with reassortant influenza virus (A/MemH1N1) bearing the HA and NA of A/PR/8/34 but with all other genes derived from A/Mem.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NS2_114-121</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RTFSFQLI</LinearSequence>
                                        <StartingPosition>114</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>138967</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system. At 10 days post challenge, the epitope-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T cells comprised 9.5 % of the virus-specific T cells in a C57BL/6 host, 12.8% of the virus-specific T cells in a C57BL/6 perforin-deficient host  and 14.3% of the virus-specific T cells in a C57BL/6 FasL-deficient host.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15892</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>8-12 wks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385640</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1x</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NS2_114-121</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RTFSFQLI</LinearSequence>
                                        <StartingPosition>114</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>138967</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>385640</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Similar results were seen when the infected host was C57BL/6-gld (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6 perforin-deficient (P&lt;SUP&gt;-/-&lt;/SUP&gt;. These results suggest that the perforin and Fas/FasL cytotoxic pathways play no major role in shaping the hierarchy of antigen-specific CD8&lt;SUP&gt;+&lt;/SUP&gt; T-cell responses in the influenza virus system. Intracellular IFN-γ was also seen when the infected host was C57BL/6 IgM&lt;SUP&gt;-/-&lt;/SUP&gt;  (FasL&lt;SUP&gt;-/-&lt;/SUP&gt;) or C57BL/6  Igm&lt;SUP&gt;-/-&lt;/SUP&gt; (Perforin&lt;SUP&gt;-/-&lt;/SUP&gt;. However, a large portion of the IgM&lt;SUP&gt;-/-&lt;/SUP&gt;-P&lt;SUP&gt;-/-&lt;/SUP&gt; mice were unable to able to efficiently clear virus between days 7 and 10. This suggests that antiviral protection is more efficiently mediated via perforin than by FasL-dependent pathways in a host without antiviral antibodies.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

